Ketamine-Assisted Psychotherapy (KAP) is an evidence-based treatment model that combines ketamine administration with structured psychotherapy, generally delivered in preparation, dosing, and integration phases. A growing body of peer-reviewed clinical research evaluates ketamine’s efficacy across depression, anxiety, trauma-related disorders, suicidality, and substance use disorders. The studies cited below include randomized controlled trials, open-label investigations, and real-world clinical analyses. While methodologies and sample sizes vary, findings consistently demonstrate rapid symptom reduction across several psychiatric conditions, particularly treatment-resistant populations.
Below is a curated list of key clinical studies and systematic reviews on KAP from 2018 to 2026 (updated in February 2026):
2026 | Ketamine-assisted psychotherapist for mental disorders: A historical overview and systematic review
2026 | Ketamine-assisted psychotherapies for mental disorders: A historical overview and systematic review
2025 | Combining Ketamine Infusions and Written Exposure Therapy for Chronic PTSD: An Open-Label Trial
2025 | The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression
2025 | Ketamine assisted psychotherapy in postpartum mood and anxiety disorders: a limited case series
2025 | Ketamine Integration Chaplaincy: A Novel Spiritual Care Approach to Psychedelic Integration
2025 | Ketamine-Assisted Psychotherapy for Addiction: Mechanisms, Evidence, and Clinical Implications
2025 | Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression: a Systematic Review
2025 | Role of ketamine in the treatment of substance use disorders: A systematic review
2025 | A long, strange trip: Ketamine treatment in psychiatry
2024 | Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective—a new and evolving approach
2024 | Underlying mechanisms of ( R,S )-ketamine’s treatment efficacy for post-traumatic stress disorder and depression: a review
2023 | Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review
2022 | A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings
2022 | Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature
2022 | Toward Synergies of Ketamine and Psychotherapy
2022 | Ketamine treatment for depression: a review
2022 | Active mechanisms of ketamine-assisted psychotherapy: A systematic review
2020 | The role of dissociation in ketamine’s antidepressant effects
2021 | Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?
2018 | Opioid Receptor Antagonism Attenuates Antidepressant Effects of Ketamine
Summary of Clinical Evidence by Indication
RCTs = Randomized Clinical Trials | TRD = treatment resistant depression | MDD = major depressive disorder
Mechanistic Considerations: Ketamine acts primarily as an NMDA receptor antagonist, resulting in increased glutamatergic signaling and downstream synaptic plasticity. Research cited on this page suggests these neurobiological effects may underlie rapid antidepressant response. Emerging models propose that transient neuroplastic changes may create a window during which psychotherapy can be particularly impactful, though controlled mechanistic trials remain ongoing.
Depression & Treatment-Resistant Depression (TRD)
Ketamine is among the most studied rapid-acting interventions for major depressive disorder and treatment-resistant depression.
Key Findings:
- Dore et al. (2019) – Retrospective review of 235 patients receiving ketamine with psychotherapy across three practices showed significant reductions in depression and anxiety symptoms, with greater improvement among patients with higher baseline severity.
- Davis et al. (2020) – Clinical data demonstrated symptom improvement across depressive disorders following structured ketamine-assisted treatment.
- Wilkinson et al. (2018) – Controlled research demonstrated that ketamine reduced suicidal ideation independently of overall antidepressant response.
Clinical Interpretation: Randomized trials and real-world data support ketamine’s rapid antidepressant effects, often observed within hours to days. Durability varies, and maintenance protocols may be required. When combined with psychotherapy, ketamine may facilitate therapeutic engagement and consolidation of gains.Evidence strength: Moderate to strong for short-term antidepressant effects; durability requires ongoing study.
Anxiety Disorders
Ketamine has been evaluated in patients with generalized anxiety symptoms and anxiety comorbid with depressive disorders.
Key Findings:
- Dore et al. (2019) – Reported statistically significant reductions in anxiety scores in patients treated with ketamine alongside psychotherapy.
- Additional cited clinical studies report reductions in anxiety symptoms in mood and trauma-related populations following ketamine administration.
Clinical Interpretation: Available data suggest clinically meaningful anxiolytic effects, particularly in patients with co-occurring depression. Dedicated large-scale randomized trials focused exclusively on primary anxiety disorders remain limited.Evidence strength: Emerging; strongest in comorbid depressive populations.
Post-Traumatic Stress Disorder (PTSD)
Ketamine has been studied in chronic PTSD and trauma-related conditions.
Key Findings:
- Randomized controlled trials cited on this page demonstrate significant reductions in PTSD symptom severity following ketamine compared to control conditions.
- Studies integrating ketamine with psychotherapy suggest potential enhancement of trauma processing, though comparative data remain limited.
Clinical Interpretation: Evidence supports short-term reduction in PTSD symptoms. Long-term durability and optimal integration protocols require further study.Evidence strength: Moderate for short-term symptom reduction.
Suicidal Ideation
Ketamine has demonstrated rapid effects on suicidal ideation across multiple randomized trials.
Key Findings:
- Wilkinson et al. (2018) – Found ketamine reduced suicidal ideation independent of overall depression improvement.
- Other randomized studies cited demonstrate rapid decreases in suicidal thoughts within hours of administration.
Clinical Interpretation: Ketamine may serve as a rapid-acting intervention for acute suicidal ideation under medical supervision. Effects may be transient without continued treatment.Evidence strength: Strong for rapid short-term reduction.
Substance Use Disorders (SUD)
Ketamine has been explored in alcohol and stimulant use disorders.
Key Findings:
- Dakwar et al. (2014) – Randomized trial found increased abstinence rates and reduced craving in cocaine-dependent individuals receiving ketamine compared to control.
- Additional studies cited suggest ketamine may enhance motivation for abstinence when combined with psychotherapy.
Clinical Interpretation: Preliminary randomized data indicate potential benefit in relapse prevention contexts. Sample sizes remain modest and further trials are required.Evidence strength: Preliminary but promising.
Obsessive-Compulsive Disorder (OCD)
Small controlled studies have investigated ketamine’s impact on obsessive-compulsive symptoms.
Key Findings:
- Short-term reductions in OCD symptom severity observed following ketamine administration in small-scale trials cited on this page.
Clinical Interpretation: Effects appear variable and durability is uncertain. Current evidence should be considered exploratory. Evidence strength: Limited / early-stage.
Palliative & Existential Distress
Ketamine has been studied in medically ill populations experiencing depressive symptoms and existential distress.
Key Findings:
- Studies cited indicate reductions in depressive symptoms and distress in supervised medical settings.
Clinical Interpretation: Evidence remains limited but suggests potential short-term benefit in palliative contexts. Evidence strength: Limited; requires further research.
Frequently Asked Questions
Does ketamine-assisted psychotherapy work for depression?
Multiple systematic reviews and RCTs show KAP produces rapid antidepressant effects, including in patients with treatment-resistant depression. A 2026 systematic review in Psychopharmacology and a 2025 review in the Journal of Affective Disorders both found significant symptom reduction, though longer-term durability remains an active area of study.
Is ketamine evidence-based?
Yes. Ketamine itself holds FDA clearance for treatment-resistant depression (as esketamine/Spravato) and off-label use of racemic ketamine is widely studied. The addition of structured psychotherapy — forming KAP — is supported by a growing body of peer-reviewed research across multiple psychiatric conditions.
What conditions is KAP studied for?
KAP has been studied for treatment-resistant depression, PTSD, generalized anxiety disorder, borderline personality disorder, substance use disorders (alcohol, addiction), eating disorders, postpartum mood disorders, and existential distress in patients with serious illness.
How does ketamine work as an antidepressant?
Ketamine acts primarily as an NMDA receptor antagonist, rapidly increasing glutamate signaling and promoting synaptic neuroplasticity. Unlike traditional antidepressants, ketamine's effects can begin within hours. Its dissociative properties may also contribute to therapeutic outcomes when paired with psychotherapy.
How quickly does ketamine reduce suicidal thoughts?
Controlled trials cited on this page report reductions in suicidal ideation within hours of administration. Effects may be transient without continued care.
Is KAP safe?
Clinical studies report KAP as generally well-tolerated when administered in clinician supervised settings. Common side effects include transient dissociation, dizziness, and nausea. Risks are managed through careful patient screening and medical oversight. Learn more about safety at Journey Clinical
Related articles
- Therapeutic alliance research
- Psychedelic-assisted psychotherapy research (beyond ketamine)
- Safety at Journey Clinical
- KAP 101: What is ketamine-assisted psychotherapy at Journey Clinical
- Ketamine and the brain
Are you a psychotherapist looking to incorporate Ketamine-Assisted Psychotherapy into your practice or a patient looking to experience KAP?